Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma

Asthma Clinical Trial

Official title:

Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03479411
• Other study ID #: 601-0013
• Status: Completed
• Phase: Phase 1
• Start date: February 9, 2018
• Est. completion date: June 28, 2018

Study information

• Verified date: July 2018
• Source: Pulmatrix Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1, 3-part study to assess safety, tolerability and PK of single and multiple doses of itraconazole administered as a dry powder for inhalation (PUR1900) in healthy subjects (parts 1 and 2) and a 2-period crossover study of single doses of itraconazole administered as a dry powder for inhalation (PUR1900) and an oral solution (Sporanox) in adults with mild to moderate, stable asthma (part 3)

Description:

Phase 1, multi-center, 3-part, open-label study in healthy adults (Parts 1 and 2) and adults with mild to moderate, stable asthma (Part 3).

Safety, tolerability and PK will be assessed following either single ascending (SAD) or multiple ascending (MAD) dosing of itraconazole administered as a dry powder for inhalation (PUR1900; Part 1 and Part 2, respectively). Part 1 will comprise 3 separate cohorts planned to receive single doses of 5, 10 and 25 mg itraconzaole, respectively. The study will have an interleaved design; Part 2 will comprise 2 separate cohorts planned to receive daily doses of itraconazole 10 and 20 mg per day for 14 days, respectively. Part 2, Cohort 1 will commence after a review of safety data from Part 1 Cohort 2 suggests it is safe to do so.

Part 3 is a 2-period, randomised, crossover study in adult subjects with mild to moderate stable asthma to assess the safety, tolerability and PK of single doses of itraconazole administered as a dry powder for inhalation (PUR1900) and administered as an oral solution (Sporanox® Oral Solution).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: June 28, 2018
• Est. primary completion date: June 28, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Part 1 (SAD) and Part 2 (MAD):

1. Healthy males or non-pregnant, non-lactating healthy females.

2. Age 18 to 60 years

3. Screening forced expiratory volume in 1 sec (FEV1) =80% of the predicted value

4. Screening FEV1/forced vital capacity (FVC) >0.70.

5. Able to demonstrate the correct inhalation technique for use of delivery device during the study.

Part 3 (Asthmatic Subjects):

1. Males or non-pregnant, non-lactating females with a physician-confirmed diagnosis of asthma for at least 3 months. Asthma must be assessed by investigator as being stable for at least 4 weeks prior to screening.

2. Age 18 to 60 years

3. Subject is being treated with either inhaled corticosteroids (ICS) or inhaled corticosteroids plus long-acting beta-agonists (ICS/LABA). Only GINA STEP 2 and 3 patients will be enrolled.

4. Pre-bronchodilator, clinic measured, FEV1 =70% of predicted normal at screening

5. Able to perform the required spirometric testing.

6. Able to produce a sputum sample of a quality required for drug concentration assessments (a single repeat is permitted).

Exclusion Criteria:

1. Subjects who have received any IMP in a clinical research study within the previous 3 months prior to dosing on this study

2. Subjects who have previously received IMP in this study. Subjects who have participated in Part 1 are not permitted to participate in Part 2 or Part 3.

3. History of any drug or alcohol abuse in the past 2 years prior to screening.

4. Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months

5. Females of childbearing potential who are pregnant or lactating, or who plan to become pregnant during the study (all female subjects must have a negative pregnancy test at screening). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy, bilateral tubal occlusion/ligation) or is postmenopausal (had no menses for 12 months without an alternative medical cause (will be re-assessed at admission/pre-dose).

6. Positive drugs of abuse test result at screening or admission

7. Subjects with congestive heart failure or a history of congestive heart failure

8. History of severe cough or bronchospasm upon inhalation of any dry powder inhalation product

9. Subjects who are taking or have taken any herbal remedies or CYP3A4 inducers in the 28 days prior to the first IMP administration

10. Upper respiratory tract infection (excluding otitis media), fever, acute or chronic cough within 14 days of the first IMP administration, or lower respiratory tract infection within the last 3 months prior to IMP administration

11. Recent (last 4 weeks prior to IMP administration) clinically significant bacterial, viral or fungal infection that required systemic (oral or intravenous) antibiotics, antivirals or antifungals; topical treatments, other than antifungals, are allowed.

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Itraconazole Powder
Itraconazole administered as a dry powder for inhalation (PUR1900)
• Itraconazole 200 mg
Sporanox® Oral Solution

Locations

Country	Name	City	State
United Kingdom	Medicines Evaluation Unit	Manchester
United Kingdom	Quotient Sciences	Nottingham

Sponsors (1)

Lead Sponsor	Collaborator
Pulmatrix Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Maximum Concentration [Cmax] of itraconazole and hydroxyitraconazole in sputum	Exploratory objective: To characterize the concentrations of itraconazole in induced sputum after single doses of inhaled PUR1900 and oral Sporanox® solution in subjects with mild to moderate stable asthma	Part 3: baseline through 28 days
Other	Area under the Curve [AUC] of itraconazole and hydroxyitraconazole in sputum	Exploratory objective: To characterize the concentrations of itraconazole in induced sputum after single doses of inhaled PUR1900 and oral Sporanox® solution in subjects with mild to moderate stable asthma	Part 3: baseline through 28 days
Primary	Number of participants with treatment-related Adverse Events as assessed by CTCAE v4.0	Safety and tolerability will be assessed by evaluating the number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Area under the serum concentration vs time curve from time 0 to infinity (AUC0-inf) of single dose of itraconazole	The area under the serum concentration vs time curve from time 0 to infinity (AUC0-inf)	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Time of the maximum measured serum concentration (Tmax) of single dose of itraconazole	Time of the maximum measured serum concentration (Tmax)	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Area under the serum concentration vs time curve within the dosing interval (AUCtau) of single dose of itraconazole	The area under the serum concentration vs time curve within the dosing interval (AUCtau)	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Apparent first-order terminal elimination half-life (t1/2 ) of single dose of itraconazole	Apparent first-order terminal elimination half-life (t1/2 )	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration vs time curve (Kel) of single dose of itraconazole	Apparent first-order terminal elimination rate constant calculated from a semi-log plot of	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Apparent clearance (CL/F) of single dose of itraconazole	Apparent clearance (CL/F)	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28
Secondary	Apparent volume of distribution (Vz/F) of single dose of itraconazole	Apparent volume of distribution (Vz/F)	Part 1: Baseline through Day 14, Part 2 and 3: Baseline through Day 28